Welcome to our dedicated page for Kodiak Sciences news (Ticker: KOD), a resource for investors and traders seeking the latest updates and insights on Kodiak Sciences stock.
Kodiak Sciences Inc. (Nasdaq: KOD) is a precommercial, retina-focused biotechnology company whose news flow centers on clinical trial progress, scientific data presentations and capital markets activity. The company is developing biologic therapeutics for retinal vascular diseases and macular edema secondary to inflammation (MESI), built on its proprietary ABC Platform and late-stage programs tarcocimab, KSI-501 and KSI-101.
On this page, readers can follow news about Kodiak’s Phase 3 studies, including GLOW2 in diabetic retinopathy, DAYBREAK in wet age-related macular degeneration, and the PEAK and PINNACLE studies in MESI. Company press releases describe milestones such as completion of enrollment in pivotal trials, new data from the Phase 1b APEX study of KSI-101, and updates on the performance of tarcocimab and KSI-501 in retinal vascular indications.
Kodiak Sciences also issues news about participation in major scientific and investor conferences, where its management and clinical collaborators present data on retinal programs and discuss the potential of IL-6 and VEGF targeting in eye disease. In addition, investors will find announcements related to public offerings of common stock and other financing activities, which the company uses to support its late-stage development and manufacturing efforts.
For anyone tracking KOD stock or developments in retinal biotechnology, this news feed offers a centralized view of Kodiak Sciences’ clinical, scientific and corporate updates as it advances its portfolio of investigational retinal medicines.
Harbour BioMed (HKEX: 02142) reported strong 2025 interim results, with total revenue reaching $101.3 million, up 327% year-over-year, and net profit soaring 51-fold to $73.0 million. The company's cash position strengthened to $320 million, a 92% increase from year-end 2024.
Key developments include the BLA acceptance for batoclimab by NMPA for gMG treatment, strategic collaborations with AstraZeneca ($105M equity investment), Windward Bio for HBM9378, and Otsuka for HBM7020. The company advanced multiple clinical-stage programs including porustobart and HBM1020, while expanding its next-generation portfolio with HBM7004 and HBM7020.
The company launched Élancé Therapeutics for obesity treatment and strengthened its platform potential through Nona Biosciences, establishing multiple global partnerships and introducing the AI-assisted Hu-mAtrIx™ drug discovery engine.
Kodiak Sciences (NASDAQ:KOD), a precommercial retina-focused biotech company, will present its glaucoma pipeline programs at the American Chemical Society Fall 2025 Meeting on August 19, 2025, in Washington, D.C.
The company is developing dual-mechanism therapies using its Antibody Biopolymer Conjugate Drug (ABCD) platform. The treatment combines a NLRP3 inhibitor targeting neuroinflammation with an IOP-lowering agent, delivered via quarterly intravitreal injection. Additionally, Kodiak is advancing its VETi™ program, an AI-enabled wearable headset designed to improve clinical trial testing efficiency and accuracy.
Kodiak Sciences (NASDAQ: KOD) reported Q2 2025 financial results and business updates, highlighting progress across its late-stage clinical pipeline. The company's three key assets - tarcocimab, KSI-501, and KSI-101 - are advancing with multiple Phase 3 readouts expected between 1Q 2026 and 1Q 2027.
Notable highlights include promising KSI-101 Phase 1b data in MESI patients, showing rapid anatomical improvements and >90% achieving dryness by week 8. Financially, Kodiak reported a net loss of $54.3 million ($1.03 per share) and ended Q2 with $104.2 million cash, expected to fund operations into 2026. R&D expenses increased to $42.8 million, while G&A expenses decreased to $12.8 million.
Kodiak Sciences (NASDAQ: KOD), a precommercial retina-focused biotechnology company, will host a virtual investor R&D Day on July 16, 2025, from 4:00 PM to 5:30 PM ET. The event will showcase the company's three late-phase clinical assets - tarcocimab, KSI-501, and KSI-101 - with presentations from senior leadership and industry experts.
The company's ABC Platform® uses molecular engineering to combine protein-based and chemistry-based therapies for treating retinal diseases. All three clinical assets are targeting Phase 3 topline data in 2026. The event will be accessible via webcast, with recording available 24 hours after the presentation.
Kodiak Sciences (NASDAQ:KOD) announced its participation in the 2025 Congress of the International Ocular Inflammation Society (IOIS) in Rio de Janeiro, where management and key opinion leaders will present highlights of KSI-101, their investigational treatment for macular edema secondary to inflammation (MESI).
KSI-101 is a first-in-class bispecific intravitreal biologic designed to simultaneously target both interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF). The presentation will address MESI pathophysiology, current treatment limitations, and clinical data for KSI-101. The breakfast symposium is scheduled for June 27, 2025, at 7:00 AM BRT.
Kodiak Sciences (KOD) reported its Q1 2025 financial results and business updates. The company ended Q1 with $138.9 million in cash, expected to fund operations into 2026. The quarter saw a net loss of $57.5 million ($1.09 per share), compared to $43.0 million ($0.82 per share) in Q1 2024. R&D expenses increased to $43.6 million from $29.9 million year-over-year, while G&A expenses slightly decreased to $15.4 million.
The company is advancing as a precommercial stage retina-focused biotech with three Phase 3 assets targeting topline data in 2026. Kodiak plans to host an Investor R&D Update on July 16, 2025, featuring updates on their pipeline including Tarcocimab (GLOW2 and DAYBREAK studies), KSI-501, and KSI-101's APEX Phase 1b trial results.
Kodiak Sciences (KOD) has reported its Q4 and full year 2024 financial results, highlighting progress across its pipeline. The company ended Q4 2024 with $168.1 million in cash, expected to support operations into 2026. The Q4 net loss was $44.1 million ($0.84 per share), compared to $59.5 million in Q4 2023.
Key developments include two Phase 3 studies for tarcocimab: GLOW2 and DAYBREAK, with topline data expected in 1Q and 2Q 2026 respectively. The company plans to file a single BLA in 2026 for wet AMD, retinal vein occlusion, and diabetic retinopathy indications. KSI-501 is being evaluated in the DAYBREAK study, while KSI-101 received FDA Orphan Drug Designation and is progressing in the APEX Phase 1b trial.
R&D expenses decreased to $31.8 million in Q4 2024 from $46.6 million in Q4 2023, while G&A expenses reduced to $14.4 million from $16.7 million year-over-year.
Kodiak Sciences (KOD) has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer for diabetic retinopathy (DR). The study successfully randomized over 250 patients, surpassing the enrollment target. Topline clinical data is expected in Q1 2026, following the 48-week treatment duration.
The GLOW2 design mirrors the successful GLOW1 study, with an additional loading dose for provider flexibility. This represents Kodiak's second registrational study in DR. The company plans to file a single BLA for tarcocimab covering wet AMD, DR, and RVO after receiving DAYBREAK topline data in Q2 2026.
The treatment shows promise with only 4 doses required in Year 1 and bi-annual dosing thereafter, addressing the current challenge where less than 1% of DR patients receive treatment due to the high frequency of injections required with existing therapies.